Abstract
The review by Toshchakov and Javmen provides a comprehensive and authoritative perspective on the current state of development of cell-permeable peptide inhibitors of TLR signaling, the field to which the authors have become major contributors. The subject of this manuscript is important not only because of the importance of TLR in health and disease, but also because this approach might present a comprehensive strategy to targeting a potentially wide range of medically important signaling pathways. Although cell-permeable peptides have not found a clinical use yet, the results obtained in small animal models are quite striking and clearly demonstrate potential of this approach for development of candidate drugs or drug leads.